n of CA | n | pyrs | IR | |
---|---|---|---|---|
Characteristics at baseline | ||||
Age (per 10 yrs increase) | ||||
Female | 52 | 3,917 | 9,687 | 5.4 |
Male | 22 | 1,081 | 2,554 | 8.6 |
Co-morbid conditions: | ||||
COPD | ||||
No | 63 | 4,754 | 11,677 | 5.4 |
Yes | 11 | 244 | 564 | 19.5 |
Gastrointestinal disease | ||||
No | 61 | 4,579 | 11,153 | 5.5 |
Yes | 13 | 419 | 1,088 | 11.9 |
Renal disease | ||||
No | 70 | 4,835 | 11,884 | 5.9 |
Yes | 4 | 163 | 357 | 11.2 |
Characteristics at follow-up | ||||
DAS28 | ||||
<3.2 | 6 | 787 | 2,165 | 2.8 |
3.2 to 5.1 | 34 | 2,823 | 7,341 | 4.6 |
>5.1 | 34 | 1,388 | 2,735 | 12.4 |
Ever exposed to | ||||
Conventional DMARDs only | 30 | 1,684 # | 3,561 | 8.4 |
Anti-TNF agents | 44 | 3,651 * | 8,558 | 5.1 |
Anakinra | 5 | 247 $ | 690 | 7.2 |